what this node claims
AlphaFold metrics / IGF1R
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
53%
low debt pressure
21%
78%structureusable
pLDDT 78.02
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 78.02
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 78.02
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
1367 residues / min 23.3 / max 98.0 / source alphafold db
Very high
43.6%
596 residues / >=90
Confident
31.6%
432 residues / 70-89
Low
9.1%
124 residues / 50-69
Very low
15.7%
215 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 1367 of 1367 residues.
- residues 1286-1367 / mean 32.12
- residues 723-774 / mean 39.62
- residues 1-30 / mean 36.96
- residues 675-704 / mean 38.91
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.